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Abstract
Background. Little is known about potential harmful effects as a consequence of self-guided
internet-based cognitive behaviour therapy (iCBT), such as symptom deterioration rates.
Thus, safety concerns remain and hamper the implementation of self-guided iCBT into clin-
ical practice. We aimed to conduct an individual participant data (IPD) meta-analysis to
determine the prevalence of clinically significant deterioration (symptom worsening) in adults
with depressive symptoms who received self-guided iCBT compared with control conditions.
Several socio-demographic, clinical and study-level variables were tested as potential modera-
tors of deterioration.
Methods. Randomised controlled trials that reported results of self-guided iCBT compared
with control conditions in adults with symptoms of depression were selected. Mixed effects
models with participants nested within studies were used to examine possible clinically signifi-
cant deterioration rates.
Results. Thirteen out of 16 eligible trials were included in the present IPD meta-analysis. Of
the 3805 participants analysed, 7.2% showed clinically significant deterioration (5.8% and
9.1% of participants in the intervention and control groups, respectively). Participants in
self-guided iCBT were less likely to deteriorate (OR 0.62, p < 0.001) compared with control
conditions. None of the examined participant- and study-level moderators were significantly
associated with deterioration rates.
Conclusions. Self-guided iCBT has a lower rate of negative outcomes on symptoms than con-
trol conditions and could be a first step treatment approach for adult depression as well as an
alternative to watchful waiting in general practice.
Introduction
Depression is a common and major health issue that is associated with a considerable personal
and societal burden (Reddy, 2010; Lepine & Briley, 2011). Self-guided forms of internet-based
cognitive behaviour therapy (iCBT) can increase accessibility and
reduce the costs of depression treatment (Hedman et al. 2012;
Muñoz et al. 2015). Over the past decade, free or commercially
provided self-guided iCBT programmes have been made available
to individuals with depression (Kaltenthaler et al. 2006). However,
there is an ongoing discussion about the advantages and disad-
vantages of such programmes (Andersson & Titov, 2014). Many
healthcare systems remain hesitant to implement self-guided iCBT.
Among the barriers to implementation are concerns regarding safety
and effectiveness (Waller & Gilbody, 2009). Offered as first stage
treatment, self-guided iCBT has been criticised as potentially delay-
ing individuals suffering from depression receiving effective clinical
services (Robinson et al. 1998; Ybarra & Eaton, 2005).
Our recent individual participant data (IPD) meta-analysis
demonstrated that self-guided iCBT produces encouraging effects
although average effects are small in magnitude (Karyotaki et al.
2017). Small effects can be clinically useful and relevant, for instance
in countries where mental healthcare services are scarce or inaccess-
ible for other reasons (Muñoz et al. 2015; Karyotaki et al. 2017).
Despite the ample evidence regarding the overall benefits of iCBT,
possible effects harmful to individuals have been infrequently mon-
itored. As with any other potentially effective treatment, iCBT could
also result in undesirable outcomes or fail to arrest substantial
ongoing deterioration (Dimidjian & Hollon, 2010). The issue of
negative effects is crucial for clinical decision-making, yet limited
systematic examination of this issue exists for iCBT.
In contrast to the vast majority of pharmacological trials,
which rigorously measure and report adverse outcomes, only
half of psychotherapeutic trials report undesirable outcomes, in
particular substantial symptom deterioration (Jonsson et al.
2014; Vaughan et al. 2014). Previous research has shown that
some forms of psychotherapy can be hazardous for some patients
e.g. prolonged imaginal exposure may result in worsening of
symptoms in some patients with posttraumatic stress disorder
(Foa et al. 2005). With regard to self-guided psychological treat-
ment, it has been argued that it may not be appropriate for all
individuals (Newman, 2000). For instance, self-guided interven-
tions may not be intensive enough for individuals with severe
symptoms (Mohr et al. 1990). Moreover, lack of therapeutic sup-
port may jeopardise therapy outcomes as the progress of patients
is not monitored (Newman et al. 2003). Most self-guided inter-
ventions are not tailored to the current depressive status of the
individual and, accordingly, do not respond to symptom deterior-
ation (Andersson & Titov, 2014).
To our knowledge symptom deterioration has not been exam-
ined in self-guided iCBT to date. It is therefore clearly important
to determine the prevalence and extent of symptom deterioration
in self-guided iCBT. Furthermore, given that not everyone
receiving self-guided iCBT experiences worsening of symptoms,
research examining for whom this particular form of therapy
may be harmful is sorely needed: individuals likely to deteriorate
could be diverted to other more appropriate treatment options.
However, study-level meta-analyses and randomised controlled
trials (RCTs) cannot thoroughly examine moderators of deterior-
ation due to inadequate power (Bower et al. 2013). Novel meth-
odological approaches, such as IPD meta-analysis, are needed to
identify who may experience adverse effects from self-guided
iCBT. IPD meta-analysis allows us to move beyond the ‘grand
mean’ to explore change at the individual level as well as to exam-
ine study variability (e.g. level of adherence, settings, etc.)
The present IPD meta-analysis examined rates of clinically sig-
nificant symptom deterioration under self-guided iCBT compared
with control conditions in adults with depression. In addition, we
examined several socio-demographic and clinical variables as
potential moderators of symptom deterioration. In the context of
the present paper, the term ‘self-guided iCBT’ is defined as CBT
treatment delivered via the Internet without any professional sup-
port related to the therapeutic content. The present analysis focuses
on the prevalence of deterioration (numbers of persons affected) in
contrast to our previous IPD meta-analysis of the present dataset in
which we focused on population average outcomes due to self-
guided iCBT on depression severity (Karyotaki et al. 2017)
Methods
Studies selection process
We included IPD from randomised controlled trials comparing
self-guided iCBT to a control condition (waiting list, treatment
as usual, attention placebo or other non-active controls) for adults
(⩾18 years old) with symptoms of depression based either on a
diagnostic interview or validated self-report scales. We excluded
studies that did not primarily target depression. No limits were
applied for language and publication status.
To identify eligible studies, we used an existing database of trials
focusing on psychological therapies for adults with depression
(Cuijpers et al. 2008). This database was developed in 2006 and
is updated annually by a systematic literature search in four
major bibliographic databases (PubMed, Embase, PsycINFO and
Cochrane Library). The database was updated up to 1 January
2016 for the current search. In this search, various index and free
terms of psychotherapy were used in combination with index
and free terms of depression. Appendix A. presents the full elec-
tronic search string for PubMed. Two reviewers (PC and EK)
examined 13 384 titles and abstracts independently. All full texts
of papers that possibly met inclusion criteria according to one of
the two reviewers were retrieved and checked for eligibility.
Disagreement on the inclusion was solved through discussion.
Additionally, references of recently published meta-analyses on
this field were examined to ensure the inclusion of all eligible pub-
lished trials. Finally, key researchers who are actively involved in
this field were contacted to ask whether they were aware of unpub-
lished trials on this topic or trials missed through the searches.
Data collection process and data items
We contacted the first or the senior author of the RCTs to request
access to their datasets. In the case of no response, a reminder
email was sent after 2 weeks and after 1 month. If no response was
received 1 month after the first email, the study was excluded as
unavailable. Authors provided IPD including socio-demographic
variables (age, gender, educational level, employment status and
relationship status), pre- and post-treatment depression scores,
anxiety scores at baseline and the number of iCBT modules com-
pleted by each participant. All IPD were merged into one dataset.
We also extracted study level variables available from the pub-
lished reports of the included RCTs (type of control condition,
recruitment method and level of support provided).
Risk of bias assessment
Two independent reviewers (EK and PC) assessed the risk of bias
in the included studies according to the Cochrane risk of bias
assessment tool (Higgins & Altman, 2008; Higgins & Green,
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2011). We examined whether the included studies were at low or
high risk of selection, performance, detection, attrition, reporting
and other sources of bias. In cases of uncertainty, clarification was
sought from the authors of the RCT.
Measures
The included studies used either the Beck Depression Inventory
[BDI-I (Beck et al. 1961) or BDI-II (Beck et al. 1996)], the
Centre for Epidemiological Studies Depression Scale [CES-D
(Radloff, 1977)] or the Patient Health Questionnaire [PHQ-9
(Kroenke et al. 2001)] as outcome measures of depression severity.
We classified ‘clinically significant deterioration’ according to
each participant’s reliable change index (RCI) (Jacobson &
Truax, 1991), which is the most commonly used method for cal-
culating clinically significant negative effects. This method aims to
ensure that each individual’s deterioration could not attributable
to measurement error (Lambert et al. 1993) and thus might war-
rant clinical intervention in the context of an unsupervised inter-
vention such as iCBT. An RCI of ±1.96 indicates that the
difference in scores is likely to be due to a real change in symp-
toms of an individual (95% confidence level). Participants show-
ing a clinically significant change with an increase in their score
(clinically significant negative change of more than −1.96) were
classified as clinically significant deteriorated (Jacobson &
Truax, 1991). A RCI was calculated separately for each of the
studies, using their pre-treatment standard deviation, and the
test–retest reliability coefficient of the outcome measure (BDI =
0.93, CES-D = 0.87, PHQ-9 = 0.84).
Finally, in a sensitivity analysis we calculated ‘any deterior-
ation’ as any increase of equal or more than one point on depres-
sive symptom scales (increase ⩾1 BDI or CES-D or PHQ-9 point)
from pre- to post-treatments. Any deterioration includes all
deterioration rates (clinically significant or not).
Missing data
Missing outcome data at the post-treatment were multiply
imputed. We generated one hundred imputed datasets based on
the missing-at-random assumption (‘mi impute mvn’ in Stata ver-
sion 13.1; StataCorp LP). These datasets, which consisted of the
observed and the imputed deterioration rates, were analysed sep-
arately using the selected model and the results were combined
using Rubin’s rules (Rubin, 2004). We ran sensitivity analyses
including only observed values to ensure the robustness of the
results (‘the complete case analysis’).
Analysis
One-stage IPD
We performed a one-stage IPD meta-analysis in which the IPD
from all included studies were merged, with participants nested
within studies. A one-stage IPD approach is preferred over a two-
stage approach because it allows for a more exact likelihood speci-
fication (Stewart & Parmar, 1993; Debray et al. 2013; Burke et al.
2016). We used the statistical software Stata (version 14.2) for con-
ducting all analyses. A multilevel-mixed effects logistic regression
was used to analyse the effect of the iCBT intervention on clinically
significant deterioration and any deterioration. We used a random
intercepts model with a random effect for each trial and fixed effect
for condition (intervention v. control) using the ‘melogit’ command
in Stata. The binary variables ‘clinically significant deterioration’
and ‘any deterioration’ were used as fixed effect.
To explore the variation in outcomes between participants, we
examined dichotomous and continuous baseline characteristics of
the participants as potential moderators of clinically significant
deterioration and of any deterioration. Moderation was tested
by adding the interaction between each moderator and deterior-
ation rates to the multilevel mixed-effects logistic regression
model. Similarly, we examined whether adherence (defined as
number of modules completed divided by the total number of
treatment modules) predicted lower deterioration rates within
the intervention group.
Two-stage IPD
In addition to the one-stage IPD, we performed a two-stage IPD to
examine the effects of study-level variables. We calculated the odds
ratio (OR) of deterioration for each study and we pooled the out-
comes using a random effects model, chosen because considerable
heterogeneity across studies was expected. The OR shows the prob-
ability that an event (deterioration) will occur in the intervention
group (self-guided iCBT) compared with the probability that the
same event occurring in the control group. An OR of more than
1 indicates increased probability that an event will occur in the
intervention group while and an OR <1 shows increased probabil-
ity that an event will occur in the control group (Deeks et al. 2008).
To examine heterogeneity, the I2-statistic was calculated. This is
an indicator of heterogeneity expressed as a percentage: an I2 value
of 0% is interpreted as no heterogeneity, 25% as low, 50% as mod-
erate and 75% as high heterogeneity (Cohen, 1988). We calculated
the 95% confidence intervals (CI) around I2 using the non-central
chi-squared-based approach within the heterogeneity module for
Stata (Orsini et al. 2006; Evangelou et al. 2007). Publication bias
was examined by visually inspecting funnel plots and by using
the Duval and Tweedie’s trim and fill method, which yields an esti-
mate of the effect size after adjusting for publication bias (Egger
et al. 1997; Duval & Tweedie, 2000). We also conducted the
Egger’s test of the intercept to quantify the bias captured by the
funnel plot and test whether it was significant30.
Finally, we examined study-level moderators by conducting
subgroup analyses using the mixed effects models in which stud-
ies were treated as random effects and subgroups were tested as
fixed effects.
Sample representativeness
In our previous analysis (Karyotaki et al. 2017), we tested differ-
ences between 13 studies that provided IPD and three eligible
studies that did not. Results indicated that there are no statistically
significant differences in depression severity outcomes between
the included and the unavailable trials (Karyotaki et al. 2017).
This suggests that the present sample of studies is representative.
However, we could not test differences between included and
unavailable trials in the current analysis since deterioration rates
are not reported by the published reports of the unavailable trials.
Results
Study selection
The systematic literature search resulted in 16 eligible studies for
inclusion. The flowchart of the study selection process is
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presented in Fig. 1. Data were available from thirteen trials includ-
ing 3876 participants (Christensen et al. 2004; de Graaf et al.
2009; Berger et al. 2011; Farrer et al. 2011; Gilbody et al. 2015;
Karyotaki et al. 2017 accepted, Spek et al. 2007; Meyer et al.
2009; Moritz et al. 2012; Phillips et al. 2014; Kleiboer et al.
2015; Meyer et al. 2015; Klein et al. 2016; Mira et al. 2017).
Three eligible datasets were excluded from the present IPD
meta-analysis as data were unavailable (Clarke et al. 2002;
Clarke et al. 2005; Clarke et al. 2009).
Studies and participants characteristics
Studies characteristics are presented in Table 1. Across the 13
included RCTs participants were recruited mainly within
Fig. 1. PRISMA IPD diagram of studies selection process.
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Table 1. Characteristics of included studies
Study (year) Inclusion criteria
Outcome
measure
Intervention
programme
Number
of
modules
Number of
participants –
intervention
Technical
support
Control
condition
Number of
participants –
controls
Post-treatment
assessment Country
Berger et al.
(2011)
BDI-II > 13; major
depression or dysthymia
according to DSM-IV
(Mini-DIPS)
BDI-II Deprexis 11 25 No WL 26 10 weeks CH, DE
Christensen
et al. (2004)
K10⩾ 22 CES-D Moodgym 5 182 No AP 178 6 weeks AU
De Graaf
et al. (2009)
BDI-II⩾ 16; BDI-II Colour Your
Life
9 200 No TAU 100 8 weeks NL
Farrer et al.
(2011)
K10⩾ 22 CES-D BluePages;
MoodGYM
5 83 Yes NT 35 6 weeks AU
Gilbody et al.
(2015)
PHQ-9⩾ 10 PHQ-9 Beating the
Blues;
8
5
452 Yes TAU 239 16 weeks UK
Kleiboer
et al. (2015)
39⩾ CES-D ⩾ 16;
15 > HADS⩾ 8
CES-D Alles Onder
Controle
5 107 No WL 106 6 weeks NL
Klein et al.
(2016)a
5⩾ PHQ-9 ⩾ 14 PHQ-9 Deprexis 11 192 Yes TAU 187 12 weeks DE
Meyer et al.
(2009)
Completed at least half of
the baseline BDI
BDI Deprexis 11 320 No WL 76 9 weeks DE
Meyer et al.
(2015)
PHQ-9⩾ 15 PHQ-9 Deprexis 11 78 No TAU 85 12 weeks DE
Mira et al.
(2017)
BDI-II < 28; experiencing
at least one stressful
event that produces
interference.
BDI-II Smiling is Fun 8 80 Yes WL 44 12 weeks ES
Moritz et al.
(2012)
Minimal to severe
depression: BDI > 0
BDI Deprexis 11 105 No WL 105 8 weeks DE
Phillips et al.
(2014)
PHQ-9⩾ 2 on five of the
nine items, including ⩾2
on item 1 or item 2.
PHQ-9 MoodGYM 5 318 No AP 319 6 weeks UK
Spek et al.
(2007)
EDS⩾ 12; no compliance
with the DSM-IV
diagnostic criteria of
depression (WHO CIDI)
BDI-II Colour Your
Life
10 67 No WL 58 10 weeks NL
AP, Attention Placebo; BDI, Beck Depression Inventory; CBT, Cognitive Behavioural Therapy; CES-D, Centre of Epidemiological Studies for Depression Scale; EDS, Edinburgh Depression Scale; HADS, Hospital Anxiety and Depression Scale; IPT,
Interpersonal Psychotherapy; K10, Kessler 10 Psychological Distress Scale; Mini DIPS, Mini Diagnostic Interview for Psychiatric Disorders; n, number; NT, no treatment; PHQ-9, Patient Health Questionnaire; PST, Problem Solving Therapy; TAU, treatment
as usual; WL: waiting list; WHO CIDI, World Health Organization Composite International Diagnostic Interview.
aKlein et al. 2016 trial provided therapeutic support to participants with moderate depression (PHQ-9 > 9). Participants with mild depressive symptoms received no support throughout the trial. Klein et al. 2016 stratified participants based on
depression severity during randomisation. Therefore, we decided to exclude all participants who received therapeutic support (PHQ-9 > 9; n = 634) from the present IPD meta-analysis.
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communities. The studies were conducted in six countries
(Australia, Germany, Spain, Switzerland, the Netherlands and
the UK). The included RCTs examined the effects of self-guided
iCBT over control conditions (attention placebo, no treatment,
treatment as usual or waiting list). The interventions consisted
of five to 11 online self-guided modules. The majority of the trials
provided fully self-guided iCBT while four studies provided tech-
nical support related to technical aspects of the web-platform.
Patient characteristics of the intervention and control groups
are presented in Table 2. There were no significant between-group
differences in gender, age, relationship status, employment, edu-
cation level, comorbid anxiety or pre-treatment scores on depres-
sion measures. Two-thirds of the participants were female (n =
2531/3832, 66%), and the mean age was 42 years (S.D. = 11.7).
Most of the participants were employed (n = 2233/3146, 71%)
and had a high school degree or further education (n = 2314/
2574, 90%). Participants had mean baseline scores of BDI-II =
28.3 (S.D. = 14.4), CES-D = 25.7 (S.D. = 10.8) and PHQ-9 = 14.2
(S.D. = 5.4). A small number of individual cases (n = 71) did not
start the treatment or did not have baseline data, leaving a total
of n = 3805. Finally, 997 participants dropped out from the
included RCTs and did not provide post-treatment scores of
depressive symptoms (26% of the total sample). More specifically,
630/2220 (28.4%) and 347/1585 (22%) participants dropped out
of the intervention and controls, respectively. The intervention
had significantly higher study dropout rates compared with con-
trols (OR 1.51, 95% CI 1.11–2.08; p = 0.01).
Assessment of risk of bias
The overall risk of bias was low across the included RCTs. Random
sequence was adequately generated and allocation was concealed in
all included studies. Blinding of participants and personnel is not
possible in psychotherapy research due to the nature of the treat-
ment. The included RCTs used self-report outcome measure,
thus blinding of outcome assessment is not applicable. As an
attempt to minimise attrition bias, we multiply imputed the miss-
ing data in the present IPD. Finally, there was no indication of
selective reporting and other sources of bias. For a justification of
risk of bias assessment for each study, the reader is referred to
our previous publication (Karyotaki et al. 2017).
Prevalence of clinically significant deterioration
Overall, 7.2% (276/3805) of participants met criteria for clini-
cally significant deterioration, while 30.1% (1143/3805) showed
deterioration of any size. Divided by treatment group, 5.8% of
participants who followed self-guided iCBT and 9.1% of partici-
pants in control groups showed clinically significant deterioration.
Similarly, 26.2% of participants in self-guided iCBT and 35.3% of
participants in control groups experienced any deterioration.
Complete case analysis showed that 6.1 and 9.1% of participants
showed clinically significant deterioration in self-guided iCBT and
control groups, respectively. Any deterioration rates were 26.5%
for self-guided iCBT and 36.6% for the control groups.
One-stage IPD: deterioration rates
The outcomes of one-stage IPD meta-analysis on deterioration rates
are summarised in Table 3. Self-guided iCBT resulted in signifi-
cantly lower clinically significant deterioration (OR 0.62; 95% CI
0.46–0.83, p < 0.001) compared with controls at post-treatment
assessment (6–16 weeks post-randomisation). Sensitivity analysis
on any deterioration rates and complete case analyses yielded simi-
lar outcomes, suggesting that these findings are robust. No signifi-
cant associations were found between participant characteristics
(age, gender, educational level, relationship status, employment sta-
tus, comorbid anxiety and baseline severity of depression) or for
deterioration rates in both full sample and complete case analyses.
Finally, treatment adherence was not significantly associated with
clinically significant (β =−0.01; S.E. = 0.37, p = 0.97) or any deterior-
ation (β =−0.10; S.E. = 0.19, p = 0.59) within the intervention group.
Table 2. Sociodemographic and clinical characteristics of study participants
Patient characteristics (n = 3847)
Intervention group
(n = 2244)
Control group
(n = 1603)
Gender female, n (%) 1507/2244 (67.4) 1024/1603 (64.2)
Age in years (mean ± S.D.) 41.37 ± 12.27 42.49 ± 11.99
In a relationship, n (%) 1239/2124 (58.3) 881/1489 (59.2)
Employed, n (%) 1306/1862 (70.1) 927/1255 (73.9)
Education level, n (%) Low 154/1593 (9.7) 106/981 (10.8)
Middle 869/1593 (54.6) 499/981 (50.9)
High 570/1593 (35.8) 376/981 (38.3)
Pre-treatment depression scores (mean ± S.D.) BDI-II 27.60 ± 13.5 29.67 ± 15.9
CES-D 26.21 ± 10.8 25.25 ± 10.9
PHQ-9 14.44 ± 5.4 13.8 ± 5.6
Post-treatment depression scores (mean ± S.D.) BDI-II 20.36 ± 14.4 25.97 ± 16.7
CES-D 18.6 ± 11.2 22.04 ± 12.2
PHQ-9 9.19 ± 6.0 9.63 ± 5.9
Comorbid anxiety disorder, n (%) 425/972 (43.7) 336/789 (42.6)
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Table 3. Relative odds of deterioration under self-guided iCBT v. controls in one-stage IPD analysis
‘Clinically significant deterioration’ ‘Any deterioration’
Full sample Complete casesa Full sample Complete casesa
Variable
Nobs
(Nst) OR (95% CI) p
Nobs
(Nst) OR (95% CI) p
Nobs
(Nst) OR (95% CI) p
Nobs
(Nst) OR (95% CI) p
Main effects – deterioration
Treatment group 3795 0.62 (0.46–0.83) 0.001 2818 0.61 (0.46–0.83) 0.001 3795 0.65 (0.55–0.76) <0.001 2818 0.66 (0.56–0.77) <0.001
(13) (13) (13) (13)
Age
Treatment group 3786 0.36 (0.13–1.00) 0.05 2809 3.22 (1.10–9.47) 0.04 3786 0.66 (0.36–1.18) 0.16 2809 0.68 (0.38–1.22) 0.20
Age × Treatment group (13) 1.01(0.99–1.03) 0.27 (13) 1.02 (1.00–1.04) 0.19 (13) 1.00 (0.98–1.02) 0.96 (13) 1.00 (0.98–1.02) 0.93
Gender
Treatment group 3788 0.61(0.43–.87) 0.008 2811 0.61 (0.42–.88) 0.008 3788 0.61 (0.50–0.74) <0.001 2811 0.61 (0.50–0.74) <0.001
Gender × Treatment group (13) 1.02 (0.58–1.80) 0.96 (13) 1.05 (0.58–1.89) 0.87 (13) 1.20 (0.86–1.67) 0.28 (13) 1.27 (0.89–1.81) 0.18
Educational level
Treatment group 2538 0.57 (0.23–1.44) 0.23 1973 0.59 (0.23–1.52) 0.28 2538 0.46 (0.26–0.83) 0.01 1973 0.46 (0.25–0.84) 0.01
Educational level × Treatment group (10) (10) (10) (10)
Secondary v. primary education 1.48 (0.51–4.26) 0.48 0.65 (0.22–1.91) 0.43 1.57 (0.82–2.99) 0.18 1.67 (0.86–3.24) 0.14
Tertiary v. primary education 0.99 (0.34–2.91) 0.98 0.90 (0.30–2.71) 0.86 1.27 (0.65–2.48) 0.47 1.25 (0.63–2.47) 0.53
Relationship status
Treatment group 3568 0.58 (0.37–0.91) 0.02 2630 0.59 (0.38–0.92) 0.02 3568 0.61 (0.48–0.80) <0.001 2630 0.63 (0.48–0.81) <0.001
Relationship status × Treatment group (12) 1.15 (0.64–2.07) 0.63 (12) 1.12 (0.78–1.59) 0.71 (12) 1.02 (0.75–1.40) 0.88 (12) 1.01 (0.71–1.44) 0.96
Employment status
Treatment group 3067 0.66 (0.40–1.09) 0.11 2194 0.70 (0.41–1.18) 0.18 3067 0.55 (0.40–0.77) <0.001 2194 0.57 (0.40–0.80) 0.001
Employment status × Treatment group (10) 0.97 (0.14–6.50) 0.92 (10) 0.92 (0.48–1.76) 0.82 (10) 1.22 (0.83–1.81) 0.32 (10) 1.21 (0.80–1.83) 0.36
Comorbid anxiety
Treatment group 1728 0.58 (0.37–0.91) 0.02 1447 0.85 (0.37–0.91) 0.02 1728 0.58 (0.43–0.77) <0.001 1447 0.57 (0.42–.76) <0.001
Comorbid anxiety × Treatment group (9) 1.13 (0.57–2.26) 0.72 (9) 1.22 (0.60–2.47) 0.57 (9) 1.04 (0.68–1.60) 0.85 (9) 1.12 (0.71–1.75) 0.64
Baseline severity of depression
Treatment group 3795 0.61 (0.44–0.85) 0.003 2818 0.61 (0.44–0.85) 0.003 3795 0.65 (0.54–0.77) <0.001 2818 0.66 (0.56–.79) <0.001
Baseline severity × Treatment group (13) 0.99 (0.74–1.33) 0.92 (13) 0.99 (0.72–1.35) 0.93 (13) 1.06 (0.91–1.24) 0.46 (13) 1.11 (0.94–1.29) 0.21
Nobs, Number of observations; Nst, number of studies; OR, odds ratio; S.E., standard error
aThis is a sensitivity analysis that was conducted including only participants who completed post-treatment depression questionnaires
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Table 4. Relative odds of deterioration of self-guided iCBT v. controls in adults with depressive symptoms, two-stage IPD
Outcomes
‘Reliable deterioration’ ‘Any deterioration’
N OR (95% CI)a I2 (%) 95% CI pb N OR (95% CI)a I2 (%) 95% CI pb
Full sample 13 0.62 (0.48–0.81) 0 0–57% 0.000 13 0.63 (0.51–0.77) 41 0–69% 0.000
Subgroups
Type of control
TAU v. 4 0.76 (0.51–1.13) 15 0–85% 0.16 4 0.68 (0.45–1.03) 63 0–88% 0.62
Other 9 0.51 (0.35–0.75) 0 0–65% 9 0.60 (0.47–0.76) 31 0–68%
Recruitment
Community 7 0.47 (0.30–0.74) 0 0–71% 0.29 7 0.56 (0.41–0.75) 36 0–73% 0.39
Community and/or primary care 4 0.76 (0.51–1.13) 15 0–85% 4 0.68 (0.45–1.03) 63 0–88%
Other 2 0.64 (0.32–1.30) 0 N/A 2 0.75 (0.54–1.03) 0 N/A
Support
Pure self-guided iCBT 9 0.61 (0.45–0.83) 0 0–65% 0.82 9 0.59 (0.46–0.77) 48 0–76% 0.34
Technically supported iCBT 4 0.66 (0.39–1.13) 0 0–85% 4 0.72 (0.53–0.96) 16 0–87%
Complete case 13 0.61 (0.45–0.83) 0 0–57% 0.000 13 0.61 (0.48–0.79) 50 5–74% 0.000
Subgroups
Type of control
TAU v. 4 0.85 (0.501.44) 36 0–78% 0.06 4 0.69 (0.40–1.19) 74 26–91% 0.56
Other 9 0.43 (0.27–0.70) 0 0–65% 9 0.59 (0.44–0.76) 31 0–68%
Recruitment
Community 7 0.40 (0.23–0.70) 0 0–71% 0.16 7 0.54 (0.37–0.79) 47 0–77% 0.69
Community and/or primary care 4 0.85 (0.50–1.44) 36 0–78% 4 0.69 (0.40–1.19) 74 26–91%
Other 2 0.56 (0.19–1.59) 0 N/A 2 0.67 (0.44–1.01) 0 N/A
Support
Pure self-guided iCBT 9 0.60 (0.43–0.85) 0 0–65% 0.85 9 0.57 (0.41–0.78) 53 0–78% 0.34
Technically supported iCBT 4 0.65 (0.34–1.23) 3 0–85% 4 0.73 (0.49–0.80) 40 0–80%
I2, heterogeneity index; N, number of studies; N/A, not applicable; OR, odds ratio.
a95% CI 95% confidence intervals; p, p-value.
bp value between groups.
Psychological
M
edicine
2463
Two-stage IPD deterioration rates
Results of the two-stage IPD meta-analysis replicated the findings
of one-stage IPD on clinically significant deterioration (OR 0.62;
95% CI 0.48–0.81, p < 0.001). Heterogeneity was zero. These results
were replicated in sensitivity analysis on any deterioration rates
showed similar outcomes and complete case analyses. There was
no indication for publication bias across all the analyses. Finally,
the examined study-level variables were not significantly associated
with clinically significant and any deterioration. Results of the two-
stage IPD are presented in Table 4 in the online supplement.
Discussion
The present IPD meta-analysis aimed to examine the clinically
significant symptom deterioration rates of self-guided iCBT
compared with controls and to evaluate the moderating effects
of deterioration. Of the 3805 participants included in the analysis,
7.2% showed clinically significant deterioration. Self-guided iCBT
had low clinically significant deterioration rates (5.8%) and
resulted in lower risk of clinically significant deterioration com-
pared with controls at the post-treatment assessment. Similar
results were observed in sensitivity analyses. None of the exam-
ined participant- and study-level variables moderated clinically
significant deterioration.
This is the first meta-analysis to have systematically examined
deterioration rates in self-guided iCBT for adults with depressive
symptoms. The finding that self-guided iCBT shows lower deteri-
oration rates compared with controls is consistent with previous
IPD meta-analysis of 2079 participants on guided internet based
interventions (Ebert et al. 2016). According to this work, guided
web-based interventions resulted in lower risk of clinically signifi-
cant deterioration compared with controls. Furthermore, guided
internet-based interventions showed 3.6% clinically significant
deterioration, which is slightly lower but comparable with the pre-
sent clinically significant deterioration rates of self-guided iCBT
(5.8%) (Ebert et al. 2016). The deterioration rates found in the
present IPD meta-analysis are in line with the deterioration rates
observed in face-to-face treatment (5–10%) (Rozental et al. 2014)
and considerably lower compared with the 12% rate of deterior-
ation reported by a recent meta-analysis examining change
under treatment as usual (Kolovos et al. 2017).
The present study has several notable strengths; we were able
to obtain IPD from 3876 participants from the majority (81%)
of the eligible trials. This large number of participants offered
us adequate power to detect statistically significant differences
between self-guided iCBT and controls on symptom deterioration
rates and to examine moderators of clinically significant deterior-
ation. In addition, the current sample of studies appears to be free
from critical bias, since the included trials had high methodo-
logical quality. Other strengths of the current work are that het-
erogeneity between studies was small to moderate and there was
no indication of publication bias.
Nevertheless, the current findings should be interpreted with
caution due to a number of limitations. The present sample of
studies is at (relatively low) risk of availability bias since three
eligible studies were not available for inclusion. The published
reports of these unavailable trials did not include deterioration
rates. Thus, traditional meta-analysis of direct comparison
between available and unavailable studies was not possible.
However, results of a previous analysis showed no difference
between the effectiveness of the available and unavailable studies,
indicating that the present sample is representative (Karyotaki
et al. 2017). Moreover, the intervention had significantly higher
study dropout rates compared with control conditions. It has
been suggested that study dropout could be either related to
symptom deterioration or improvement (Rozental et al. 2014).
On the other hand, higher study adherence rates in controls,
such as waiting list, may be associated to the expectation that par-
ticipants will eventually receive treatment. Unfortunately, it was
not possible to examine reasons for study dropout as this infor-
mation is largely missing from the included studies. In light of
this limitation, it should be noted that in the present analysis
missing outcome data were multiply imputed based on missing
at random assumption. The missing at random assumption
underlying multiple imputation is critical as it assumes that
those participants for whom post-treatment data were imputed
behaved similarly to those with post-treatment data with compar-
able profiles. Therefore, if individuals dropped out due to deteri-
oration (missing not at random), this would not be captured and
a conservative estimate of deterioration is likely. Nevertheless, we
performed a complete case analysis to test the robustness of our
main full sample analysis and we found no differences between
the full sample and complete cases in deterioration rates.
Another limitation is that we could not examine several variables
that might influence deterioration, such as previous episodes of
depression and symptom duration. Individuals who have experi-
enced several episodes of depression in the past and those who
have chronic symptoms might be at greater risk of deterioration.
Moreover, the majority of the trials included recruited their par-
ticipants through the community. Thus, the current findings can-
not be generalised to patients treated in clinical settings since
active care seekers may differ from individuals responding to
advertisements.
From a clinical point of view, the present study has important
implications. Although many patients prefer psychotherapy to
antidepressants (van Schaik et al. 2004), pharmacotherapy domi-
nates primary and secondary mental healthcare while psychother-
apy is offered to a lesser degree. Self-guided iCBT has the
potential to increase the availability and accessibility of psycho-
therapy and minimise the costs. However, the implementation
of self-guided iCBT in clinical practice is hampered by barriers,
such as concerns regarding its safety and effectiveness. The pre-
sent study has demonstrated that self-guided iCBT results in
lower risk for symptom deterioration compared with controls
(including regular care services) and our previous study showed
that is effective in treating depressive symptoms. This suggests
that self-guided iCBT could be an alternative to watchful waiting
in general practice and it can be disseminated at a large scale in
countries where resources of mental healthcare are limited or
inaccessible due to other reasons.
Symptom deterioration occurs in self-guided iCBT and study
dropout is higher compared with controls; thus, future studies
should carefully examine and report deterioration rates and rea-
sons for study dropout. Future research on self-guided iCBT
interventions should examine deterioration rates over longer
time periods. Moreover, moderators, such as duration of symp-
toms and previous episodes, should be addressed by future studies
to indicate for whom self-guided iCBT might be harmful. More
studies from primary care are needed to replicate the current find-
ings with clinical samples.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291718000648
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